George Du Toit1, Graham Roberts, Peter H Sayre, Henry T Bahnson, Suzana Radulovic, Alexandra F Santos, Helen A Brough, Deborah Phippard, Monica Basting, Mary Feeney, Victor Turcanu, Michelle L Sever, Margarita Gomez Lorenzo, Marshall Plaut, Gideon Lack. 1. From the Department of Pediatric Allergy, Division of Asthma, Allergy and Lung Biology, King's College London and Guy's and St. Thomas' National Health Service Foundation Trust, London (G.D.T., S.R., A.F.S., H.A.B., M.B., M.F., V.T., G.L.), and the University of Southampton and National Institute for Health Research Respiratory Biomedical Research Unit, Southampton and David Hide Centre, Newport, Isle of Wight (G.R.) - both in the United Kingdom; the Division of Hematology-Oncology, Department of Medicine (P.H.S.), and the Immune Tolerance Network (D.P.), University of California, San Francisco, San Francisco; Rho Federal Systems Division, Chapel Hill, NC (H.T.B., M.L.S.); and the National Institute of Allergy and Infectious Diseases, Bethesda, MD (M.G.L., M.P.).
Abstract
BACKGROUND: The prevalence of peanut allergy among children in Western countries has doubled in the past 10 years, and peanut allergy is becoming apparent in Africa and Asia. We evaluated strategies of peanut consumption and avoidance to determine which strategy is most effective in preventing the development of peanut allergy in infants at high risk for the allergy. METHODS: We randomly assigned 640 infants with severe eczema, egg allergy, or both to consume or avoid peanuts until 60 months of age. Participants, who were at least 4 months but younger than 11 months of age at randomization, were assigned to separate study cohorts on the basis of preexisting sensitivity to peanut extract, which was determined with the use of a skin-prick test--one consisting of participants with no measurable wheal after testing and the other consisting of those with a wheal measuring 1 to 4 mm in diameter. The primary outcome, which was assessed independently in each cohort, was the proportion of participants with peanut allergy at 60 months of age. RESULTS: Among the 530 infants in the intention-to-treat population who initially had negative results on the skin-prick test, the prevalence of peanut allergy at 60 months of age was 13.7% in the avoidance group and 1.9% in the consumption group (P<0.001). Among the 98 participants in the intention-to-treat population who initially had positive test results, the prevalence of peanut allergy was 35.3% in the avoidance group and 10.6% in the consumption group (P=0.004). There was no significant between-group difference in the incidence of serious adverse events. Increases in levels of peanut-specific IgG4 antibody occurred predominantly in the consumption group; a greater percentage of participants in the avoidance group had elevated titers of peanut-specific IgE antibody. A larger wheal on the skin-prick test and a lower ratio of peanut-specific IgG4:IgE were associated with peanut allergy. CONCLUSIONS: The early introduction of peanuts significantly decreased the frequency of the development of peanut allergy among children at high risk for this allergy and modulated immune responses to peanuts. (Funded by the National Institute of Allergy and Infectious Diseases and others; ClinicalTrials.gov number, NCT00329784.).
BACKGROUND: The prevalence of peanut allergy among children in Western countries has doubled in the past 10 years, and peanut allergy is becoming apparent in Africa and Asia. We evaluated strategies of peanut consumption and avoidance to determine which strategy is most effective in preventing the development of peanut allergy in infants at high risk for the allergy. METHODS: We randomly assigned 640 infants with severe eczema, egg allergy, or both to consume or avoid peanuts until 60 months of age. Participants, who were at least 4 months but younger than 11 months of age at randomization, were assigned to separate study cohorts on the basis of preexisting sensitivity to peanut extract, which was determined with the use of a skin-prick test--one consisting of participants with no measurable wheal after testing and the other consisting of those with a wheal measuring 1 to 4 mm in diameter. The primary outcome, which was assessed independently in each cohort, was the proportion of participants with peanut allergy at 60 months of age. RESULTS: Among the 530 infants in the intention-to-treat population who initially had negative results on the skin-prick test, the prevalence of peanut allergy at 60 months of age was 13.7% in the avoidance group and 1.9% in the consumption group (P<0.001). Among the 98 participants in the intention-to-treat population who initially had positive test results, the prevalence of peanut allergy was 35.3% in the avoidance group and 10.6% in the consumption group (P=0.004). There was no significant between-group difference in the incidence of serious adverse events. Increases in levels of peanut-specific IgG4 antibody occurred predominantly in the consumption group; a greater percentage of participants in the avoidance group had elevated titers of peanut-specific IgE antibody. A larger wheal on the skin-prick test and a lower ratio of peanut-specific IgG4:IgE were associated with peanut allergy. CONCLUSIONS: The early introduction of peanuts significantly decreased the frequency of the development of peanut allergy among children at high risk for this allergy and modulated immune responses to peanuts. (Funded by the National Institute of Allergy and Infectious Diseases and others; ClinicalTrials.gov number, NCT00329784.).
Authors: Claudia L Gray; Michael E Levin; Heather J Zar; Paul C Potter; Nonhlanhla P Khumalo; Lucia Volkwyn; Bartha Fenemore; George du Toit Journal: Pediatr Allergy Immunol Date: 2014-10 Impact factor: 6.377
Authors: Alexandra F Santos; Louisa K James; Henry T Bahnson; Mohammed H Shamji; Natália C Couto-Francisco; Sabita Islam; Sally Houghton; Andrew T Clark; Alick Stephens; Victor Turcanu; Stephen R Durham; Hannah J Gould; Gideon Lack Journal: J Allergy Clin Immunol Date: 2015-02-07 Impact factor: 10.793
Authors: D de Silva; M Geromi; S Halken; A Host; S S Panesar; A Muraro; T Werfel; K Hoffmann-Sommergruber; G Roberts; V Cardona; A E J Dubois; L K Poulsen; R Van Ree; B Vlieg-Boerstra; I Agache; K Grimshaw; L O'Mahony; C Venter; S H Arshad; A Sheikh Journal: Allergy Date: 2014-01-16 Impact factor: 13.146
Authors: Aikaterini Sofianou-Katsoulis; David Mesher; Peter Sasieni; George Du Toit; Adam T Fox; Gideon Lack Journal: World Allergy Organ J Date: 2011-02-23 Impact factor: 4.084
Authors: Susan L Prescott; Ruby Pawankar; Katrina J Allen; Dianne E Campbell; John Kh Sinn; Alessandro Fiocchi; Motohiro Ebisawa; Hugh A Sampson; Kirsten Beyer; Bee-Wah Lee Journal: World Allergy Organ J Date: 2013-12-04 Impact factor: 4.084
Authors: Brian P Vickery; Jelena P Berglund; Caitlin M Burk; Jason P Fine; Edwin H Kim; Jung In Kim; Corinne A Keet; Michael Kulis; Kelly G Orgel; Rishu Guo; Pamela H Steele; Yamini V Virkud; Ping Ye; Benjamin L Wright; Robert A Wood; A Wesley Burks Journal: J Allergy Clin Immunol Date: 2016-08-10 Impact factor: 10.793
Authors: Ruchi S Gupta; Christopher M Warren; Bridget M Smith; Jesse A Blumenstock; Jialing Jiang; Matthew M Davis; Kari C Nadeau Journal: Pediatrics Date: 2018-11-19 Impact factor: 7.124